Fig. 1

ANGPTL4 increases energy charge to fuel ABC transporters activity. a Heatmap showing fold change in the mRNA expression of multiple ABC transporters in three in vitro EMT models. n = 3 independent experiments. b FACS analysis of cell surface expression of indicated ABC transporters, ABCB1 (left panel), ABCC1 (middle panel) and ABCG2 (right panel) in hypoxia- and TGF-β1-induced EMT of MKN74 cells. Data are represented as mean ± s.d. from at least five independent experiments. c-d Relative fluorescence signal of efflux assay measuring drug efflux capacity of MKN74 and MKN74_Snai1ER cells in all three in vitro EMT models (c), and in the presence of selective ABC transporters inhibitors Verapamil, MK-571 and Novobiocin (d). Data are represented as mean ± s.d. from at least five independent experiments. *P < 0.05, **P < 0.01. e Gene enrichment analysis based on gene expression data of three in vitro EMT models (GSE71280). f-g Extracellular acidification rate (f) and long chain fatty acid (LCFA) β-oxidation (g) analyses of control (MKN74_CTRL) and siRNA ANGPTL4-knockdown (MKN74_ΔANGPTL4) after indicated treatments. Values were normalized to total cellular protein. Values are represented as mean ± s.d. from at least three independent experiments. h Graphs showing the IC₅₀ curve of MKN74_CTRL (solid line) and MKN74_ΔANGPTL4 (dotted line) to cisplatin (left panel) and doxorubicin (right panel). Values are represented as mean ± s.d. from n = 5 independent experiments. *P < 0.05, ** P < 0.01